Shares of Verona Pharma plc (NASDAQ:VRNA), a clinical-stage biopharmaceutical company focused on respiratory disease treatments, plummeted 5.95% in the pre-market trading session on Friday.
The stock's decline comes despite an analysis article suggesting that Verona Pharma is expected to break even in 2025 and become profitable in 2026, according to consensus estimates from industry analysts covering the company. The article highlights that analysts forecast an average annual growth rate of 59% for Verona Pharma to achieve profitability, which is considered optimistic.
However, the article also notes that Verona Pharma has a relatively high level of debt, with debt exceeding 92% of its equity. This high debt obligation increases the risk for investors in the loss-making company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。